Display options
Cite
Lui M, Garberich R, Strauss C, et al. Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia. J Lipids. 2014;2014:864317doi: 10.1155/2014/864317.
Lui, M., Garberich, R., Strauss, C., Davin, T., & Knickelbine, T. (2014). Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia. Journal of lipids, 2014864317. https://doi.org/10.1155/2014/864317
Lui, Matthew, et al. "Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia." Journal of lipids vol. 2014 (2014): 864317. doi: https://doi.org/10.1155/2014/864317
Lui M, Garberich R, Strauss C, Davin T, Knickelbine T. Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia. J Lipids. 2014;2014:864317. doi: 10.1155/2014/864317. Epub 2014 Oct 19. PMID: 25386364; PMCID: PMC4217354.
Copy Download .nbib Format: NLM
Share it on

J Lipids. 2014;2014:864317. doi: 10.1155/2014/864317. Epub 2014 Oct 19.

Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia.

Journal of lipids

Matthew Lui, Ross Garberich, Craig Strauss, Thomas Davin, Thomas Knickelbine

Affiliations

  1. Minneapolis Heart Institute Foundation at Abbott Northwestern Hospital, 920 E 28th Street, Minneapolis, MN 55407, USA.
  2. Minneapolis Heart Institute at Abbott Northwestern Hospital, 920 E 28th Street, Minneapolis, MN 55407, USA.
  3. Kidney Specialists of Minnesota at Abbott Northwestern Hospital, 920 E 28th Street, Minneapolis, MN 55407, USA.

PMID: 25386364 PMCID: PMC4217354 DOI: 10.1155/2014/864317

Abstract

Lipid apheresis is used to treat patients with severe hyperlipidemia by reducing low-density lipoprotein cholesterol (LDL-C). This study examines the effect of apheresis on the lipid panel and cardiac event rates before and after apheresis. An electronic health record screen of ambulatory patients identified 11 active patients undergoing lipid apheresis with 10/11 carrying a diagnosis of FH. Baseline demographics, pre- and postapheresis lipid levels, highest recorded LDL-C, cardiac events, current medications, and first apheresis treatment were recorded. Patients completed a questionnaire and self-reported risk factors and interest in alternative treatment. There were significant reductions in mean total cholesterol (-58.4%), LDL-C (-71.9%), triglycerides (-51%), high-density lipoprotein (HDL) cholesterol (-9.3%), and non-HDL (-68.2%) values. Thirty-four cardiac events were documented in 8 patients before apheresis, compared with 9 events in 5 patients after apheresis. Our survey showed a high prevalence of statin intolerance (64%), with the majority (90%) of participants indicating an interest in alternative treatment options. Our results have shown that lipid apheresis primary effect is a marked reduction in LDL-C cholesterol levels and may reduce the recurrence of cardiac events. Apheresis should be compared to the newer alternative treatment modalities in a randomized fashion due to patient interest in alternative options.

References

  1. Atherosclerosis. 2003 Mar;167(1):1-13 - PubMed
  2. Atherosclerosis. 1998 Jul;139(1):173-8 - PubMed
  3. Eur J Clin Invest. 1994 Nov;24(11):724-32 - PubMed
  4. Science. 1986 Apr 4;232(4746):34-47 - PubMed
  5. Clin Res Cardiol Suppl. 2012 Jun;7:24-30 - PubMed
  6. Circulation. 1997 Jan 7;95(1):76-82 - PubMed
  7. Int Heart J. 2005 Sep;46(5):833-43 - PubMed
  8. JAMA. 2001 May 16;285(19):2486-97 - PubMed
  9. Ther Apher Dial. 2004 Oct;8(5):383-9 - PubMed
  10. J Lipid Res. 2009 Apr;50 Suppl:S172-7 - PubMed
  11. Ther Apher Dial. 2003 Aug;7(4):419-24 - PubMed
  12. Atherosclerosis. 1992 Jul;95(1):1-13 - PubMed
  13. JAMA. 1990 Dec 19;264(23):3018-24 - PubMed
  14. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-17 - PubMed
  15. Circulation. 1996 May 15;93(10):1826-35 - PubMed
  16. Lancet. 1995 Apr 1;345(8953):811-6 - PubMed
  17. J Am Coll Cardiol. 2002 Jul 17;40(2):220-7 - PubMed
  18. Clin Chem. 2004 Oct;50(10):1725-32 - PubMed

Publication Types